Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, accounting for approximately 70% of dementia cases worldwide. Patients gradually exhibit cognitive decline, such as memory loss, aphasia, and changes in personality and behavior. Research has shown that mitochondrial dysfunction...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1484373/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841540126097801216 |
|---|---|
| author | Shuguang Wang Zuning Liao Qiying Zhang Xinyuan Han Changqing Liu Jin Wang |
| author_facet | Shuguang Wang Zuning Liao Qiying Zhang Xinyuan Han Changqing Liu Jin Wang |
| author_sort | Shuguang Wang |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most common neurodegenerative disorder, accounting for approximately 70% of dementia cases worldwide. Patients gradually exhibit cognitive decline, such as memory loss, aphasia, and changes in personality and behavior. Research has shown that mitochondrial dysfunction plays a critical role in the onset and progression of AD. Mitochondrial dysfunction primarily leads to increased oxidative stress, imbalances in mitochondrial dynamics, impaired mitophagy, and mitochondrial genome abnormalities. These mitochondrial abnormalities are closely associated with amyloid-beta and tau protein pathology, collectively accelerating the neurodegenerative process. This review summarizes the role of mitochondria in the development of AD, the latest research progress, and explores the potential of mitochondria-targeted therapeutic strategies for AD. Targeting mitochondria-related pathways may significantly improve the quality of life for AD patients in the future. |
| format | Article |
| id | doaj-art-7db431acf6f64d6badfb40398373958f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7db431acf6f64d6badfb40398373958f2025-01-14T05:10:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14843731484373Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapiesShuguang Wang0Zuning Liao1Qiying Zhang2Xinyuan Han3Changqing Liu4Jin Wang5College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaDepartment of Neurology, Fourth People’s Hospital of Jinan, Jinan, ChinaDepartment of Internal Medicine, Jinan Municipal Government Hospital, Jinan, ChinaCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaAlzheimer’s disease (AD) is the most common neurodegenerative disorder, accounting for approximately 70% of dementia cases worldwide. Patients gradually exhibit cognitive decline, such as memory loss, aphasia, and changes in personality and behavior. Research has shown that mitochondrial dysfunction plays a critical role in the onset and progression of AD. Mitochondrial dysfunction primarily leads to increased oxidative stress, imbalances in mitochondrial dynamics, impaired mitophagy, and mitochondrial genome abnormalities. These mitochondrial abnormalities are closely associated with amyloid-beta and tau protein pathology, collectively accelerating the neurodegenerative process. This review summarizes the role of mitochondria in the development of AD, the latest research progress, and explores the potential of mitochondria-targeted therapeutic strategies for AD. Targeting mitochondria-related pathways may significantly improve the quality of life for AD patients in the future.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1484373/fullmitochondriaADdysfunctionmechanismstherapeutic targets |
| spellingShingle | Shuguang Wang Zuning Liao Qiying Zhang Xinyuan Han Changqing Liu Jin Wang Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies Frontiers in Immunology mitochondria AD dysfunction mechanisms therapeutic targets |
| title | Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies |
| title_full | Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies |
| title_fullStr | Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies |
| title_full_unstemmed | Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies |
| title_short | Mitochondrial dysfunction in Alzheimer’s disease: a key frontier for future targeted therapies |
| title_sort | mitochondrial dysfunction in alzheimer s disease a key frontier for future targeted therapies |
| topic | mitochondria AD dysfunction mechanisms therapeutic targets |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1484373/full |
| work_keys_str_mv | AT shuguangwang mitochondrialdysfunctioninalzheimersdiseaseakeyfrontierforfuturetargetedtherapies AT zuningliao mitochondrialdysfunctioninalzheimersdiseaseakeyfrontierforfuturetargetedtherapies AT qiyingzhang mitochondrialdysfunctioninalzheimersdiseaseakeyfrontierforfuturetargetedtherapies AT xinyuanhan mitochondrialdysfunctioninalzheimersdiseaseakeyfrontierforfuturetargetedtherapies AT changqingliu mitochondrialdysfunctioninalzheimersdiseaseakeyfrontierforfuturetargetedtherapies AT jinwang mitochondrialdysfunctioninalzheimersdiseaseakeyfrontierforfuturetargetedtherapies |